ES2601029T3 - Derivado de ciclosporina - Google Patents

Derivado de ciclosporina Download PDF

Info

Publication number
ES2601029T3
ES2601029T3 ES12751509.6T ES12751509T ES2601029T3 ES 2601029 T3 ES2601029 T3 ES 2601029T3 ES 12751509 T ES12751509 T ES 12751509T ES 2601029 T3 ES2601029 T3 ES 2601029T3
Authority
ES
Spain
Prior art keywords
alkyl
group
formula
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12751509.6T
Other languages
English (en)
Spanish (es)
Inventor
Gunter Fischer
Miroslav Malesevic
Frank Erdmann
Jan KÜHLING
Michael Bukrinsky
Stephanie Constant
Gerd Rühter
Peter Nussbaumer
Klaus Dinkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Original Assignee
Lead Discovery Center GmbH
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV filed Critical Lead Discovery Center GmbH
Application granted granted Critical
Publication of ES2601029T3 publication Critical patent/ES2601029T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
ES12751509.6T 2011-08-30 2012-08-29 Derivado de ciclosporina Active ES2601029T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011111991A DE102011111991A1 (de) 2011-08-30 2011-08-30 Neue Cyclosporin-Derivate
DE102011111991 2011-08-30
PCT/EP2012/066726 WO2013030208A1 (de) 2011-08-30 2012-08-29 Cyclosporin-derivate

Publications (1)

Publication Number Publication Date
ES2601029T3 true ES2601029T3 (es) 2017-02-14

Family

ID=46754993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12751509.6T Active ES2601029T3 (es) 2011-08-30 2012-08-29 Derivado de ciclosporina

Country Status (9)

Country Link
US (1) US9453051B2 (cg-RX-API-DMAC7.html)
EP (1) EP2751127B1 (cg-RX-API-DMAC7.html)
JP (1) JP6240072B2 (cg-RX-API-DMAC7.html)
CN (1) CN103842372A (cg-RX-API-DMAC7.html)
AU (1) AU2012300934B2 (cg-RX-API-DMAC7.html)
CA (1) CA2845663C (cg-RX-API-DMAC7.html)
DE (1) DE102011111991A1 (cg-RX-API-DMAC7.html)
ES (1) ES2601029T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013030208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0737730Y2 (ja) 1989-10-04 1995-08-30 横河電機株式会社 溶射装置
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
CN104513296B (zh) * 2013-09-27 2018-03-02 王喆明 一种环肽化合物及其用途
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
CA3000822A1 (en) * 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
US12594275B2 (en) 2019-02-07 2026-04-07 The Regents Of The University Of California Immunophilin binding agents and uses thereof
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021173474A1 (en) * 2020-02-26 2021-09-02 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
CA3172535A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
WO2022192716A1 (en) * 2021-03-11 2022-09-15 Massachusetts Institute Of Technology Small molecule suppressors of apoe gene expression and cerebral vascular amyloid pathology
CN112919984B (zh) * 2021-04-16 2022-03-08 安徽硒无忧现代农业科技有限公司 一种生态化富硒有机营养液及其制备方法
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1506200A (en) * 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
US4672044A (en) 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
AT401823B (de) 1993-09-30 1996-12-27 Avl Verbrennungskraft Messtech Optischer indikator zur bestimmung der aktivität eines ions in einer probe
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
PT848009E (pt) * 1996-12-16 2000-11-30 Pharmachemie Bv Processo para a preparacao de epirubicina ou seus sais de adicao de acido a partir de daunorubicina
CA2285454A1 (en) 1997-04-07 1998-10-15 Axys Pharmaceuticals Corporation Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69832984T2 (de) 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
DE19859910C2 (de) 1998-12-23 2001-03-22 Ratiopharm Gmbh Orales Arzneimittel
IL135884A (en) 2000-04-30 2005-08-31 Yissum Res Dev Co Method for measuring non-transferrin bound iron
US6596499B2 (en) 2000-11-30 2003-07-22 The Netherlands Cancer Institute Membrane molecule indicator compositions and methods
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
WO2003087089A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
AU2003285958A1 (en) 2002-10-25 2004-05-25 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
WO2005004805A2 (en) * 2003-07-02 2005-01-20 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
DE10339597A1 (de) 2003-08-26 2005-03-31 Bayer Technology Services Gmbh Vorrichtung und Verfahren zum Nachweis biochemischer Aktivität enthaltend Gap Junctions
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DE102006038403A1 (de) 2006-08-17 2008-02-21 Heinrich-Heine-Universität Düsseldorf Verwendung bestimmter chemischer Verbindungen zur Inhibierung der Peptidyl-Prolyl-cis/trans-Isomeraseaktivität von Cyclophilinen
SG144809A1 (en) 2007-01-11 2008-08-28 Millipore U K Ltd Benzimidazole compounds and their use as chromatographic ligands
PL1990405T3 (pl) * 2007-05-08 2018-01-31 Provivo Oy Genetycznie zmodyfikowane szczepy wytwarzające metabolity będące antracyklinami użyteczne jako leki przeciwnowotworowe
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
MX2011001152A (es) 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
DE102009037551A1 (de) 2009-08-17 2011-02-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate

Also Published As

Publication number Publication date
WO2013030208A1 (de) 2013-03-07
EP2751127B1 (de) 2016-07-27
CA2845663A1 (en) 2013-03-07
AU2012300934B2 (en) 2016-06-09
AU2012300934A1 (en) 2014-03-13
EP2751127A1 (de) 2014-07-09
US9453051B2 (en) 2016-09-27
CA2845663C (en) 2020-09-08
DE102011111991A1 (de) 2013-02-28
CN103842372A (zh) 2014-06-04
JP6240072B2 (ja) 2017-11-29
JP2014531417A (ja) 2014-11-27
US20140316104A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
CA2845663C (en) Cyclosporin derivatives
JP6490660B2 (ja) 活性に基づくプローブの化合物、組成物、および使用方法
BRPI0711857A2 (pt) 4-amino-pirido[3,2-e]pirazinas, uso das mesmas como inibidores de fosfodiestrase 10 e processo para a preparação das mesmas
JP7212373B2 (ja) 新規ペプトイドポリマーおよび使用方法
WO2019171042A1 (en) Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment
KR102736981B1 (ko) 악성 고형 종양 치료를 위한 병독성 약독화된 박테리아
JP7367950B2 (ja) 抗菌性ポリミキシン誘導体化合物
CN108884466A (zh) 基于细菌的蛋白递送
Colarusso et al. Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction
US9365623B2 (en) Cyanochrome fluorophores
ES2989648T3 (es) Nuevos compuestos y su uso como inhibidores selectivos de caspasa-2
US20140038902A1 (en) Method of Treating Metastatic Cancer
DK1781315T3 (en) PEPTIDE INHIBITORS FOR MEDIATION OF stress responses
ES2382289B1 (es) PÉPTIDO INHIBIDOR DE p38 Y APLICACIONES.
JP7341451B2 (ja) タンパク質性化合物とその利用
CA3206293A1 (en) Cyclic peptides and uses thereof
CA3238696A1 (en) Peptides and uses thereof
WO2025070720A1 (ja) ペプチド
HK1195916A (en) Cyclosporin derivatives
US9856300B2 (en) Dpy-30 binding peptides and methods of use
Kleinwächter Membrane Modulation and Cardiolipin Interaction of Small Molecules and Proteins
Melkumyan et al. NOVEL SYNTHETIC AMINO ACIDS AND PEPTIDES AS BACTERIAL GROWTH INHIBITORS
Class et al. Patent application title: DPY-30 Binding Peptides Inventors: Pinfen Yang (Milwaukee, WI, US) Priyanka Sivadas (Milwaukee, WI, US) Assignees: Marquette University
Trinh Regulation of vertebrate planar cell polarity
HK40038480B (en) Novel compounds and their use as selective inhibitors of caspase-2